| Trial registration number
|
NCT04862806 |
Full text link
Last imported at : April 29, 2021, 10:18 a.m.
Source : ClinicalTrials.gov
|
https://clinicaltrials.gov/show/NCT04862806
|
First author
Last imported at : April 29, 2021, 10:18 a.m.
Source : ClinicalTrials.gov
|
Tamar Tadmor, MD
|
Contact
Last imported at : April 29, 2021, 10:18 a.m.
Source : ClinicalTrials.gov
|
tamar.tadmor@b-zion.org.il
|
Registration date
Last imported at : April 29, 2021, 10:18 a.m.
Source : ClinicalTrials.gov
|
2021-04-28
|
Recruitment status
Last imported at : April 5, 2023, 8 p.m.
Source : ClinicalTrials.gov
|
Unknown
|
Study design
Last imported at : April 29, 2021, 10:18 a.m.
Source : ClinicalTrials.gov
|
nonRCT
|
Allocation
Last imported at : April 29, 2021, 10:18 a.m.
Source : ClinicalTrials.gov
|
Non-randomized
|
Design
Last imported at : April 29, 2021, 10:18 a.m.
Source : ClinicalTrials.gov
|
Single group assignment
|
Masking
Last imported at : April 29, 2021, 10:18 a.m.
Source : ClinicalTrials.gov
|
Open label
|
Center
Last imported at : March 15, 2023, 4 a.m.
Source : ClinicalTrials.gov
|
multi-center
|
Study aim
Last imported at : April 29, 2021, 10:18 a.m.
Source : ClinicalTrials.gov
|
Prevention
|
Inclusion criteria
Last imported at : April 29, 2021, 10:18 a.m.
Source : ClinicalTrials.gov
|
inclusion criteria:
- diagnosis of cll was according to the iwcll criteria
- all patients received two 30-μg doses of bnt162b2, administered intramuscularly 3
weeks apart. (pfizer).
|
Exclusion criteria
Last imported at : April 29, 2021, 10:18 a.m.
Source : ClinicalTrials.gov
|
- previous covid19 virus infection
|
Number of arms
Last imported at : April 29, 2021, 10:18 a.m.
Source : ClinicalTrials.gov
|
1
|
Funding
Last imported at : April 29, 2021, 10:18 a.m.
Source : ClinicalTrials.gov
|
Bnai Zion Medical Center
|
Inclusion age min
Last imported at : April 29, 2021, 10:18 a.m.
Source : ClinicalTrials.gov
|
18
|
Inclusion age max
Last imported at : April 29, 2021, 10:18 a.m.
Source : ClinicalTrials.gov
|
100
|
Countries
Last imported at : April 29, 2021, 10:18 a.m.
Source : ClinicalTrials.gov
|
Israel
|
Type of patients
Last imported at : April 29, 2021, 10:18 a.m.
Source : ClinicalTrials.gov
|
High risk patients
|
Severity scale
Last imported at : April 29, 2021, 10:18 a.m.
Source : ClinicalTrials.gov
|
N/A
|
Total sample size
Last imported at : April 29, 2021, 10:18 a.m.
Source : ClinicalTrials.gov
|
1000
|
primary outcome
Last imported at : Sept. 21, 2021, 5:30 a.m.
Source : ClinicalTrials.gov
|
Antibody Persistence after Third Dose of BNT162b2 mRNA COVID-19 Vaccination in Serongative Patients with Chronic Lymphocytic Leukemia;Change in the number of participants with BNT162b2 mRNA vaccine-related adverse events as assessed by a questionnaire relating to the development of patients' side effects to the vaccine, which was developed by study investigators.
|
Notes
Last imported at : April 29, 2021, 10:18 a.m.
Source : ClinicalTrials.gov
|
None
|
Phase
Last imported at : Nov. 16, 2021, 6:30 p.m.
Source : ClinicalTrials.gov
|
Not reported
|
Arms
Last imported at : April 29, 2021, 10:18 a.m.
Source : ClinicalTrials.gov
|
[{"arm_notes": "30 \u03bcg;2;Days1-21;IM", "treatment_id": 222, "treatment_name": "Bnt162b2", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}]
|